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Many autoimmune diseases are associated with autoantibody formation. Yet in
only a few instances has it been clearly established that the autoantibody associated
with the disease contributesto the pathogenic process. Cold agglutinins are autoan-
tibodies that preferentially bind to RBC membrane antigens at low temperatures
(1-3). Cold agglutinins may be pathologic, found in association with cold agglutinin
disease (CAD)' or benign, found in the sera of healthy individuals. The antigenic
specificities of benign and pathologic cold agglutinins are similar and include var-
ious glycolipids and glycoproteins (1, 4). CADhasbeen classified as either idiopathic
(i.e., not associated with an underlying disease) or secondary to lymphoid neoplasms
or infections (2). In cold agglutinin disease, whether idiopathic or secondaryto lym-
phoid neoplasms, cold agglutinins are typically IgMK monoclonal autoantibodies,
as defined by a homogeneous peak on the serum electrophoretic pattern.
To further examine the clonalityand cellular origin ofpathologic cold agglutinins
we have studied B cell clones from a patient(RR) with a spleniclymphoma associated
with immune hemolysis due to an anti-Pr2 cold autoantibody (5). Cytogenetic
studies of splenic lymphocytes demonstrated an abnormal karyotype (51, XX, +3,
+9, +12, +13, +18). After EBV transformation ofspleniclymphocytes, seven clones
were isolated; each clone had the same abnormal karyotype and secreted an IgMtc
anti-Pr2 cold agglutinin. Further studies of surface phenotype, Ig gene rearrange-
ments, and antibody specificity suggestedthat the EBVtransformed clones secreted
an RBC autoantibody that was identical to the pathogenic autoantibody causing
immune hemolysis in the patient (6). However, while the IEF spectrotypes of the
autoantibodies derived from five of the seven B cell clones were identical to the cold
agglutinin isolated from the patient's serum, two of seven clones had distinctive spec-
trotypes. This finding indicated that the EBVtransformed B cell clones were struc-
turally heterogeneous, even though they retained the same autoreactive specificity.
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Idiotypic heterogeneity of human follicular lymphomas has been ascribed to a high
rate of somatic mutations in the V region genes (7-10). If a similar somatic muta-
tional process were taking place in the autoreactive tumor described here, we would
predict that sequence variants could account for the observed spectrotypic diversity.
In this report, we have defined the molecular basis of autoantibody heterogeneity
of B cell tumor origin through nucleotide sequence analysis of both heavy (V) and
light (V,) chain variable region genes. By comparing the junctional sequences
formed by the joining of V , D, J., as well as VK and JK gene segments, we have
evaluated the clonality ofthe seven clones at a molecular level. Additionally, a com-
parison of the V region sequences has allowed us to examine the frequency of nucleotide
substitutions and to determine ifthe deduced amino acid sequences can explain the
different IEF spectrotypes observed.
Materials and Methods
RNA Isolation.
￿
RNA was prepared from LS clones (1, 2, 4, 5-8) that had been established
by EBV transformation as previously described (5). Cells (N3-5 x 108) were grown in RPMI
1640 medium (Gibco Laboratories, Grand Island, NY) with 10 0 /0 FCS. Cells were washed
twice in PBS and frozen as pellets in liquid nitrogen and stored at -70°C. Total cellular
RNA was prepared by the guanidinium isothiocyanate method as described by Chirgwin
et al. (11). Poly(A)' RNA was isolated on oligo(dT)-cellulose columns (12).
Oligonucleotide Primers.
￿
Human tt and x oligonucleotide primers were synthesized using
phosphotriester chemistry by an oligonucleotide synthesizer (Applied Biosystems, Inc., Foster
City, CA). Oligonucleotides were purified by electrophoresis through 2070 polyacrylamide/7
M urea preparative gels, followed by passive elution and separated on Sep-Pak CI8 cartridges
(Waters Associates, Milford, MA). Sequences used for Poly(A)i RNA priming were (p,) 5'-
CAGGAGACGAGGGGGAA-3' (9) and (K) 5'-AGATGGCGGGAAGATGAAGAC-3'.
cDNA Synthesis and Cloning.
￿
Double-stranded cDNA was made by the method described
by Gubler and Hoffman (13) as modified for Ig genes (14) using 5 l~g of LS series RNA.
Blunt-ended double-stranded cDNA was ligated into the phosphatased SmaI site of phagemid
pBS M13- (Stratagene, San Diego, CA). Escherichia coli strain bSJ72 was transformed by recom-
binant phagemid DNA. Even though a highly enriched library containing human immuno-
globulin genes was generated, it was necessary to screen the partial library with V (15) and
V,, (16) gene probes. Northern blot analysis of isolated RNA (data not shown) indicated that
the expressed V genes belonged to the VHI and VKIII families. Agarose gel purification of
probes proved essential since plasmid DNA would crosshybridize to the phagemid DNA on
the filters.
Sequencing of cDNA Clones.
￿
After clones were identified as containing a human heavy or
light chain cDNA insert, the phagemid clones, which contain the M13 origin of replication
were grown with helper phage K07 (17) to rescue ssDNA. Since the pBS M13 - vector yields
negative stranded ssDNA, the M13 reverse primer was used for sequencing. cDNA sequences
were determined with the method of Sanger (18) using Sequenase (United States Biochem-
ical Corp., Cleveland, OH) with [35S]dATP. 570 PAGE/8 M urea gels (Model STS 45; IBI,
New Haven, CT) were run accordingto manufacturer's recommendation. The gels were fixed,
dried, and exposed overnight to XAR5 film (Eastman Kodak Co., Rochester, NY). Sequences
were then determined and analyzed with the Wisconsin Sequence Package (19) running on
a VAX computer (Digital, Burlington, MA).
Statistical Analysis of Observed Somatic Mutations.
￿
Seven cells produced a pattern of muta-
tions having three cells either unmutated or with identical mutations and four cells each having
its own unique set of mutations. This 3-1-1-1-1 pattern was used to determine a maximum
likelihood estimate (MLE) as well as confidence bounds on the underlying mutation rate.
This was done by simulating the clonal proliferation process for this situation by adapting
a previously developed general Monte-Carlo model (20). The computer model ofcell prolifer-
ation starts with one cell and produces a random succession of left or right progeny untilSILBERSTEIN ET AL.
￿
163 3
a total of 40 divisions is reached (Fig . 1 A) . Then the same tree is restarted picking left or
right random progeny as before. This time the tree is merely followed if the chosen left or
right progeny already exists. If the tree fails to contain the requested random branch, then
anew cell is added in that direction and more new cells are again added until the 40th divi-
sion is reached . This is continued until seven strands of the tree have been extended to 40
divisions . Note that the tree would contain 240 (1 .1 x 10' 2 ) cells at its last level if completed,
but our simulation generates only seven . These seven are a random selection of the entire
set of 24° . Each new cell acquires a random number of mutations determined from the
Poisson distribution . The parameter or themean of the Poisson distribution is the mutation
rate . The mutation rate is defined by the user and we used a range to investigate the ability
of clonal development to create the observed pattern of mutations . Since each cell contains
a largenumber of independently mutating bases, each with very low probability (see Results),
the Poisson distribution is appropriate for the number of mutations per cell per division .
The chance of silent, neutral, or defunctionalizing mutations has been determined both
theoretically and empirically (20, Shlomchik, M . J ., S . Litwin, andM . Weigert, manuscript
in preparation) . The probability of each type is taken into account in generating the tree
so that the likelihood of a lineage is determined . If a pathway incurs a lethal mutation, then
the program inserts a dead cell in the tree . The creation of dead cells puts blockages in the
tree structure, since dead cells don't proliferate . Subsequent passes to generate the needed
seven cells may encounter a dead cell . If this happens the program restarts the pass . In the
FIGURE 1 . (A) Simulated clonal
proliferation showing 10 cell divi-
sions with random left/right daugh-
ters. Circles (representing individ-
ual cells) contain cell clone number.
Open cells are unmutated, light
gray cells contain one and darker
gray cells contain two mutations.
One cell at level 5 is dead . (B) Fre-
quencies ofall possible numbers of
clones generated in 1,000 trials
when the mutation rate is set at
0.031 mutations/cell/division .1634
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event that no path to 40 divisions exists by virtue of dead cells, the entire tree is aborted.
When seven cell lines have been extended to 40 divisions, the clonal identity of each cell is
determined. Two cells in the final division are regarded as identical if and only if they have
a common ancestor from which neither has mutated. The possibility that two final division
cellscontain identical, independently derived mutations is ignored since it is so improbable.
However, with a little additional programming individual base mutations could be recorded
and this possibility taken into account.
The program requests the user to specify a mutation rate, then it determines if the ob-
served pattern is likely to occur. It does this by simulating the process of cell proliferation
1,000 times, all at the same mutation rate. In each repetition the program checks ifthe seven
cellsalive at division 40 match the observed pattern. At the conclusion ofthe 1,000 repetitions
the number of times the pattern was observed is tabulated. If the seven simulated cells make
up 3 identical ones, i.e., each with either no mutations, or the same set of mutations, and
four others that are each unique, then this simulation matches the observed outcome. The
number of occurrences of this pattern among the 1,000 repetitions divided by 1,000 is an
estimate of the probability of the observed outcome for this value of the mutation rate. By
running the program several times, entering different mutation rateseach time, we can deter-
mine what rate gives the biggest tally, and hence biggest estimate of the probability of the
observation. The 1,000 trials are regarded as Bernoulli trials, and we are estimating the chance
of success, in this case, the chance of the original observation of 3-1-1-1-1. The probability
for success in a trial is the likelihood function that is to be maximized. It depends on the
mutation rate, and would be conditioned on the fact that trials that are aborted should not
be considered, since they cannot account for the observed data. It would also account for
the patterns of all possible cell lineages after 40 divisions. We note that trial abortion is very
rare at the mutation rateswe are using(see Results), namely p (aborted tree) <0.00178 (com-
putation not shown). However, we can investigate the underlying process without explicitly
knowing the likelihood function by using a computer simulation. When we run the program
at a very low mutation rate (0.001 mutations per cell per division) it rarely produces five
different clones, whereas at a high mutation rate (0.15 mutations per cell division) it produces
six or seven different clones. Thus we adjust the mutation rate to an intermediate value so
that the program reflects the observed data. By applying a series of different values for the
mutation rate we identify one that maximizes the program's production of mutational pat-
terns similar to that observed. This rate is our approximation to the maximum likelihood
estimate of the true rate. Three similar statistics are collected. First, the outcome is tested
for beingidentical to the observed 3-1-1-1-1 pattern. Next, the outcome is tested for containing
at least five clones, finally it is tested for containing no more than five clones. The last two
statistics are used to determine -95% confidence bounds on the true mutation rate. These
three statistics are tallied and the entire procedure is repeated 1,000 times. Finally, the pro-
gram outputs the number of times the observed mutational pattern was obtained as well as
the tallies of the other two statistics.
Results
Nucleotide Sequences of V H and K Regions.
￿
The V and V, region gene segments of
the seven EBV lines were cloned as cDNAs by extending an oligonucleotide primer
homologous to the 5' region of the human heavy and light chain constant regions
(Figs. 2 and 3) . The use of the 1. chain primer has been previously reported (8, 9).
The choice of the K primer was based on identifying a human CK region that was
homologous to an evolutionary conserved CK sequence from the mouse (21). The
is primer consisted of a 21mer, 18 nucleotides from the 3' end of the J segment of
a rearranged gene. Two or more independent cDNA clones were isolated and se-
quenced because of concern for sequencing or cloning artifacts. Clones were deter-
minedto be of independent origins on the basis of different cDNA sizes and orienta-
tion of inserts. Sequences of cDNA clones isolated from a particular LS cell linewere all identical indicating high fidelity ofthe reverse transcriptase. Ofthe several
thousand nucleotides sequenced, no mutation due to polymerization ofthe reverse
transcriptase was seen. Furthermore, to assess for mutations occurringdueto tissue
culture, cDNA clones ofcell lines LS2 and 5 were isolated and sequenced at 6-mo
intervals; no changes in nucleotide sequences were seen among repeat isolates.
The nucleotide sequences ofthe seven V and VI genes are shown in Figs. 2 and
3, respectively. It is evident that except for a few nucleotide substitutions, the se-
quences are almost identical. Identical V.-D., D.J., V,-J,, and N gene segments
are all consistent with a clonal origin. Clonality is further supported by the unusual
karyotype associated withthetumorand EBVtransformedcells, as wellastheSouthern
blot analyses ofheavyandlight chain locishowingidentical Ig gene rearrangements (6).
Although the sequences are nearly identical, several nucleotide substitutions are
seen that could only be attributed to somatic mutations ifall cells were in fact de-
rived from a single progenitor cell. Single T substitutions at amino acid positions
72 (LS4) and 78 (LS1) in the heavy chain gene and position 92 (LS6) in the light
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FIGURE 2.
￿
Nucleotide sequences of VH region from anti-Pr2 EBV clones. Amino acid transla-
tion is given above nucleotide sequence and numbered accordingto reference 22. Complementary-
determining regions (CDRl, CDR 2, and CDR 3), D and J4 gene segments are as indicated.
Differences from the consensus sequence (LS2) are indicated in both nucleotide and amino acid
sequences. Homology of the nucleotide with the consensus sequence on the top line is shown
as a dash. The W oligonucleotide sequence used to prime cDNA clones is indicated with an asterisk.
These sequence data have been submitted to the EMBL/GenBank Data Libraries under acces-
sion number Y00652.1636
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FIGURE 3.
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Nucleotide sequences ofVL regions from anti-Pr2 EBV clones. Aminoacid transla-
tionsis givenabovenucleotide sequence andnumbered accordingtoreference 22. Complementary-
determining regions (CDR 1 andCDR2)andJ4 gene segmentareas indicated. Differences from
theconsensussequence (LSI)are indicated. Homology of thenucleotide with the consensus se-
quence on thetop line is shown as adash. The K oligonucleotide sequence used to prime cDNA
clones is indicated with an asterisk. Thesesequence data have been submittedto theEMBL/Gen-
Bank Data Libraries.
chain gene all are silent changes andproduceno predicted amino acid changes. The
only nucleotide substitution that changes the predicted amino acid sequence is at
amino acid position 30 (LS8) in the heavy chain gene. The change (Thr-Ser) is
considered aconservative substitution sinceboth have aliphatic hydroxyl side chains
and no change in the net charge of the deduced protein is expected.
The gene sequences were compared for homology to previously published V  and
V K genes and in particular to other human RBC autoantibody sequences. The V 
sequences belong to the V 1I gene family as demonstrated by Northern blot anal-
ysis (data not shown) and were found to be 88% homologous to a germline V t gene
(Fig. 4A) (22). The LS light chain sequences were 97% homologous to a germline
VAilt gene (Fig. 4 B) (23). We have surveyed the D gene segments known to date
and have not found identical sequences (24, 25). The V region gene sequences of
the LS autoantibodies differ from another human anti-Pr2 RBC autoantibody,
which by NH2-terminal sequencing uses VIII and VKIV family genes (26). The use
of different V genes by anti-Pr2 autoantibodies suggests that the human response
to this antigen is not highly restricted.
Confidence Intervalforthe Observed Mutation Rate.
￿
To estimate the mutation frequency,
we assumed that a tumor mass of at least 1012 cells (based on weight and immuno-
histochemistry ofthe spleen) existed at the time of splenectomy and EBV transfor-
mation . From this cell mass number, we calculated that -40 (24° = 1.1 x 1012) cell
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FIGURE 4.
￿
Comparison of the VH and VK nucleotide sequences of the anti-Pr2 autoantibodies
reported here (LS lines) and(A) GL 1-1, germline VH1 gene (23); (B) GL-KVL, germline VK111
gene (24). Dashes indicate sequence homology with the LS sequence. Listed abovethe nucleotide
sequence are the position numbers of the corresponding amino acidslisted according to refer-
ence 22. Leader and CDR regions are as indicated.
divisions had taken place and on the average, 4/7 (0.571) somatic mutations percell
hadaccumulated from thesingle tumor cellto the timeofsplenectomy andtransfor-
mation. Since there are 696 by in both heavy and light chain genes, these figures
allow us to estimate a mutation frequency of0.01427 mutations/division or 2.05 x
10 -5 mutations/base pair/division (m/bp/d) (0.571/(696 bps x 40 divisions)). With
the mutation rate of0.031 mutations per cell (4.45 x 10 -5 m/bp/div) per division,
the chance oftheobservedpattern wasmaximized andwas about 27%, i.e., the 1,000
repetitions produced 266 outcomes each ofwhich contained a set ofthree identical
cells plus four completely unique cells (Fig. 1 B). This is the MLE for the mutation
rate. Setting the mutation rate to 0.0085 mutations per cell perdivision (1.22 x 10 -6
m/bp/div) the chance ofobserving at least five clones was reduced to 0.028 and by
setting it to 0.12 mutations per cell per division (1.72 x 10 -4 m/bp/div) the chance
ofobserving five or fewer clones was reduced to 0.023. Thus an approximate 95%
confidence interval for the mutation rate is(0.0085, 0.12)mutationspercellper divi-
sion and (1.22 x 10 -6 , 1.72 x 10 -4 ) mutations per base pair per division.
Ourestimate oftumorcell mutation rate rests on the assumption that tumor cells
do not die. Thus, it must be taken as an upper band until better approximations
to tumor cell birth and death rates are available.
Discussion
Thehumoral immune repertoire is produced byB lymphocytes that have the ability
to respond to a wide range ofantigenic specificities. The differentiation ofB lym-
phocytes can be divided into two stages. The first stage is antigen independent in-
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volving the development of stem cells into B cells. After acquiring antigen binding
receptors, B cells migrate to the peripheral organs such as lymph nodes and spleen
where they encounter various antigens. The second stage involves the proliferation
and subsequent differentiation of B cells into Ig-secreting plasma cells. Since au-
toantigens are ubiquitous, it follows that autoimmune responsesmust be controlled
by regulatory mechanisms such as clonal deletion and/or T cell suppression.
Although autoantibodies are associated with many autoimmune disorders, their
role in the pathogenesis of disease in most cases is unclear. In contrast, the patho-
logic role of RBC autoantibodies in immune hemolysis is well established (1). To
study the biologyof thesepathogenic RBC autoantibodies, we have established seven
EBVtransformed B cell clones from apatient (RR) with splenic lymphoma and im-
mune hemolysis due to an anti-Pr2 RBC autoantibody. Previously, we had demon-
strated that these EBVtransformed clones secreted the same pathogenic autoanti-
body as presentin the serum of thepatient. The sequence data ofthis report confirm
the clonal relatedness of these lines. By IEF analysis, however, two of seven clones
secreted autoantibodies with different spectrotypes . The different IEF banding pat-
terns could be explained by a post-translational event, such as glycosylation, or by
somatic mutation of the primary nucleotide sequence. Altered glycosylation could
result from a change in primary sequence leading to the appearance or disappear-
ance of glycosylation sites, or by variable glycosylation at a particular amino acid
without a change in the primary amino acid sequence (27). The observed somatic
mutationsin the LS cell lines areeither silent or conservative and thus do not account
for any charge differences. Although the conservative, serine to threonine substitu-
tion (LS8; V.; position 30), occurred in one of the autoantibodies with a different
spectrotype, this somatic mutation did not involve an Asn-X-Ser/Thr recognition
sequence required forN-linked glycosylation (27) . 0-linked glycosylation of a serine
residue in theV region has been reported only once in an abnormal human myloma
X light chain (28). It is therefore unlikely that the two distinctive spectrotypes result
from the nucleotide substitutions found in the V and V,, region genes of the seven
clones. Variable glycosylation and/or mutations in the Ig constant regions are alter-
native causes for spectrotypic differences and cannot be ruled out.
The small number of somatic mutations, i.e., only 4 in >5,000 bases sequenced,
shows that at the time of sampling, a low somatic mutation frequency existed in
this B cell tumor population. One can speculate that the mutation rate may have
been high at one point but then slowed or even stopped. Alternatively, a high so-
matic mutation rate may never have existed.
The idea that the mutation rate can vary in the expansion and maturation of a
B cell clone is supported by data from murine cell lines with various specificities
(including autoantigens) and representing different stages of B cell differentiation
(20, 29, 30). Mutations appear to be infrequent in the preimmune repertoire and
primary immune response (estimated at <10-5 m/bp/d) (31, 32). However, during
subsequent steps of B cell maturation, characteristic of secondary immune responses,
somataic point mutationsare introduced in a stepwise fashionat arate approximating
10-3 m/bp/d (33, 34). At later stages of B cell differentiation, as demonstrated in
studies of transformedplasma cells, somaticmutations are considered to occur again
at a lower rate (estimated mutation frequency between 10-6 and 10' m/bp/d) (35).
The type oflymphoma analyzed in this report differs in several aspectsfrom otherSILBERSTEIN ET AL.
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B cell malignancies of which V regions have been analyzed (36, 37) . First, the B
cell tumor of the patient in this report consists of early plasmacytoid cells, which
represent a more mature stage ofB cell differentiation than the types involved in
acutelymphoblastic leukemia (pre-B cell) (38), chronic lymphocytic leukemia (im-
mature-matureB cell) (39), and follicular lymphoma (follicular center cell, activated
B cell) (8, 9) . Second, theB celltumordescribed here, is unique in that its specificity
is well defined .
Based on the availableV region sequences from these four different types of B
cell lymphomas, a correlation is proposedbetween the stage ofB cell ontogeny and
the estimated mutation frequencies (see Fig . 5) . In a recent study ofVH sequence
analysis from patients of acute lymphoblastic leukemia (ALL), no somatic muta-
tions were found in >15,000 nucleotide sequences (38) . Based on this finding it was
calculated that the prevalence of mutations in theseALL tumors was <6.7 x 10 -6
m/bp/d . In the two cases of CLL, no evidence for sequence heterogeneity of ex-
pressed V genes was observed ; theV sequences isolated from two unrelated indi-
viduals are highlyhomologous to each other andto apreviously publishedgermline
FIGURE 5 .
￿
Hypothetical correlation of differentiation stage of different B cell tumors and so-
matic mutation rate. 1 . ALL ; pre-B cell ; low somatic mutation rate estimated (39) . II . CLL ;
immature-matureB cell ; low somatic mutation rate estimated (40, 41). III . Follicularlymphomas;
activated B cell, likely of follicular center cell origin ; somatic mutation rate is high (8, 9). IV
Well-differentiated lymphoma; anti-Pr2 secreting B cell lymphoma, early plasmacytoid cell type;
low somatic mutation rate estimated (this paper) . Solid line indicates somatic mutation rates esti-
mated for four types ofB cell lymphomas representing different stages ofB cell differentiation .
The dotted line reflectsthe rare occurrence ofsomatic mutations in non-Igvariable region loci (32).1640
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V sequence (39, 40). In contrast, a relatively high frequency of somatic mutation
occurs in follicular B cell lymphomas similar to the mutational process found in
normal differentiating B cells (8, 9). The mutation rate has not been determined
for these human B cell tumors, because the number of cell divisions is not known.
However, with some assumptions we have estimated the mutation rate of the lym-
phoma described in this report, to be 4.45 x 10-5 (see Results). Similarly, a muta-
tion rate hasalso been estimated for casesof ALL. Theseestimated rates imply that
somatic mutation rates that are significantly lower than those found in activated B
cells would occur in lymphomas representing both earlier and more mature stages
of differentiation (Fig. 5). We next determined if the prevalence of somatic muta-
tions was significantly different among the various types of lymphomas by comparing
the frequency of silent mutations found in the previously published VH and VL se-
quences (8, 9, 38-40). Only silent mutations were considered in order to exclude
any bias due to selection. Using Fisher's exact test for the hypergeometric distribu-
tion, the frequency of silent mutations in the plasmacytoid B cell lymphoma (3/4,992
by sequenced) was significantly lower than in follicular lymphoma (16/2,124 by se-
quenced; p < 0.00001), but was not significantly different (p > 0.5) from the observed
frequency in ALL (0/15,000) and CLL (0/1,428) (39). This difference can be ex-
plained as either ahigher mutation rate in follicular lymphomasor by the possibility
that these lymphomas represented a larger number of cell divisions allowing for a
greaternumber ofobserved mutations. The result of this statistical analysis also fits
with the proposed model illustrated in Fig. 5. Thus, this model proposes that B cell
tumors with low somatic mutation frequencies will include cases of ALL and CLL,
consisting ofpre-B and intermediate B-cells, as well as lymphomasrepresenting plas-
macytic, more mature stages of B cell differentiation.
The role of exogenousandautoantigens in clonal selectionandexpansionofantigen-
specific B cell during an immune response hasbeen studied in several animal model
systems (28-30). Although binding of sIg with autoantigen (i.e., Pr2) may be im-
portant in driving a specific B cell clone to expand, other secondary factors such
as increased oncogene expression arelikely to contribute to the malignant transfor-
mation of these autoreactive B cell clones (41, 42). This view of lymphoma develop-
ment, where clonal expansion and malignant transformation are separate and inde-
pendent events, is supportedby theobserved clinical spectrum ofcold hemagglutinin
disease (1). At one end of the spectrum are patients with an expanded B cell clone
producingamonoclonal cold agglutinin, identified as ahomogeneousband on serum
protein electrophoresis; thesepatients have no evidence forlymphoma and arediag-
nosed as having idiopathic cold hemagglutinin disease. At the otherend ofthespec-
trum are patients with the secondary form of cold hemagglutinin disease, whose
expanded B cell clone hasundergone malignant transformation; these patients present
with or eventually develop clinical lymphoma.
In summary, the low mutation frequency observed in this Pre-specific B cell
tumor, may not only be related to the tumor differentiationstage but also may reflect
selection by autoantigen to retain Ig structureand specificity. Theconserved nature
of sIg receptors expressed by B cell tumors of this type would predict a good re-
sponse to antiidiotype therapy (43). Additional studies of V genes from different
types of B cell lymphomas, representing various stages of differentiation, will con-
tribute to understanding the biology ofB cell neoplasia and also define the potential
for passive immunotherapy.SILBERSTEIN ET AL .
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Summary
To study the biology of cold agglutinin disease we previously established EBV
transformed B cell clones isolated from a patient with splenic lymphoma of an early
plasmacytic cell type and immune hemolysis due to an anti-Pr2 cold agglutinin.
These clones had an aberrant chromosomal marker identical to the patient's B cell
lymphoma and each secreted IgMk anti-Pr2 similar to the pathologic autoantibody
in the serum of the patient. In this study, we have further investigated the Pr2-
specific autoimmune response through nucleotide sequencing of VH and V,, region
genes. We have shown that the seven clones share the same VDJ/VJ gene segments
and junctional elements confirming their clonal origin. The V sequences were 88%
homologous to a VHI germline gene while the V, sequences were 97 17o homologous
to a VkIII germline gene. Only 4 somatic mutations (3 silent and 1 conservative)
were found in >5,000 by sequenced, suggesting that a low mutation rate existed.
Based on a tumor mass of 1012 cells and a minimum of 40 divisions, we estimated
the somatic mutation rate to be 4.45 x 10 -5 m/bp/d.
This somatic mutation rate is similar to those estimated for acute lymphocytic
leukemia (pre-B cell) and chronic lymphocytic leukemia (intermediate B cell), but
significantly lower than the mutation frequency in follicular lymphomas (activated
B cell). We propose that the difference in somatic mutation frequency of a B cell
tumor may be related to the stage of B cell differentiation. In addition, the low mu-
tation frequency observed in the Pr2-specific B cell tumor may also reflect, in part,
selection by autoantigen to conserve sIg structure and specificity.
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Joni Brill Dashoff and Ms. Anita Cynwinski for excellent technical help with the blots, probe
preparations, and sequencing. We are also very grateful to Dr. Martin Weigert for helpful
and constructive suggestions.
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